Skip to main content
Premium Trial:

Request an Annual Quote

Prenatal Dx Test Firm Verinata Raising $48.5M

NEW YORK (GenomeWeb News) – Fetal chromosomal abnormality test developer Verinata Health today announced it has raised about $46.5 million toward a Series C financing round that is expected to bring in a total of $48.5 million.

The San Carlos, Calif.-based company added that it expects to raise the remaining $2 million and close the round on Aug. 31.

The funds will be used to continue R&D on a non-invasive prenatal diagnostic test and subsequently commercialize it. The company's technology is based on DNA-based research at Stanford University, and Verinata is developing a sequencing-based approach to identify chromosomal aneuploidies across the entire genome, it said on its website.

Using optimized algorithms, the company analyzes DNA sequencing data to identify fetal chromosomal abnormalities, including trisomy 21 and trisomy 18. The company is evaluating the accuracy of its methods through a multi-site, blinded study with research and clinical institutions, it added.

In a statement today, Caren Mason, CEO of Verinata, said that the company expects to complete its validation study by the end of the year in preparation of a launch of the diagnostic test during the first quarter of 2012.

The current funding round was led by existing investors Mohr Davidow Ventures, Sutter Hill Ventures, and Alloy Ventures.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.